CITALOPRAM HYDROBROMIDE tablet, film coated

Citalopram Hydrobromide by

Drug Labeling and Warnings

Citalopram Hydrobromide by is a Prescription medication manufactured, distributed, or labeled by Dr. Reddy's Laboratories Limited, Dr.Reddy's Laboratories Limited. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

Other Events Observed During the Postmarketing Evaluation of Citalopram

It is estimated that over 30 million patients have been treated with citalopram since market introduction. Although no causal relationship to citalopram treatment has been found, the following adverse events have been reported to be temporally associated with citalopram treatment, and have not been described elsewhere in labeling: acute renal failure, akathisia, allergic reaction, anaphylaxis, angioedema, choreoathetosis, chest pain, delirium, dyskinesia, ecchymosis, epidermal necrolysis, erythema multiforme, gastrointestinal hemorrhage, angle closure glaucoma, grand mal convulsions, hemolytic anemia, hepatic necrosis, myoclonus, nystagmus, pancreatitis, priapism, prolactinemia, prothrombin decreased, QT prolonged, rhabdomyolysis, spontaneous abortion, thrombocytopenia, thrombosis, ventricular arrhythmia, torsade de pointes, and withdrawal syndrome.

  • DRUG ABUSE AND DEPENDENCE

    Controlled Substance Class

    Citalopram is not a controlled substance.

    Physical and Psychological Dependence

    Animal studies suggest that the abuse liability of citalopram is low. Citalopram has not been systematically studied in humans for its potential for abuse, tolerance, or physical dependence. The premarketing clinical experience with citalopram did not reveal any drug-seeking behavior. However, these observations were not systematic and it is not possible to predict, on the basis of this limited experience, the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully evaluate citalopram patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse (e.g., development of tolerance, incrementations of dose, drug-seeking behavior).

  • OVERDOSAGE

    Human Experience

    In clinical trials of citalopram, there were reports of citalopram overdose, including overdoses of up to 2000 mg, with no associated fatalities. During the postmarketing evaluation of citalopram, citalopram overdoses, including overdoses of up to 6000 mg, have been reported. As with other SSRIs, a fatal outcome in a patient who has taken an overdose of citalopram has been rarely reported.

    Symptoms most often accompanying citalopram overdose, alone or in combination with other drugs and/or alcohol, included dizziness, sweating, nausea, vomiting, tremor, somnolence, and sinus tachycardia. In more rare cases, observed symptoms included amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and very rare cases of torsade de pointes). Acute renal failure has been very rarely reported accompanying overdose.

    Management of Overdose

    Establish and maintain an airway to ensure adequate ventilation and oxygenation. Gastric evacuation by lavage and use of activated charcoal should be considered. Careful observation and cardiac and vital sign monitoring are recommended, along with general symptomatic and supportive care. Due to the large volume of distribution of citalopram, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. There are no specific antidotes for citalopram.

    In managing overdosage, consider the possibility of multiple-drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose.

  • DOSAGE AND ADMINISTRATION

    Citalopram should be administered once daily, in the morning or evening, with or without food.

    Initial Treatment

    Citalopram should be administered at an initial dose of 20 mg once daily, with an increase to a maximum dose of 40 mg/day at an interval of no less than one week. Doses above 40 mg/day are not recommended due to the risk of QT prolongation. Additionally, the only study pertinent to dose response for effectiveness did not demonstrate an advantage for the 60 mg/day dose over the 40 mg/day dose. 

    Special Populations

    20 mg/day is the maximum recommended dose for patients who are greater than 60 years of age, patients with hepatic impairment, and for CYP2C19 poor metabolizers or those patients taking cimetidine or another CYP2C19 inhibitor. (see WARNINGS)

    No dosage adjustment is necessary for patients with mild or moderate renal impairment. Citalopram should be used with caution in patients with severe renal impairment.

    Treatment of Pregnant Women During the Third Trimester

    Neonates exposed to citalopram and other SSRIs or SNRIs, late in the third trimester, have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding (see PRECAUTIONS). When treating pregnant women with citalopram during the third trimester, the physician should carefully consider the potential risks and benefits of treatment.

    Maintenance Treatment

    It is generally agreed that acute episodes of depression require several months or longer of sustained pharmacologic therapy. Systematic evaluation of citalopram in two studies has shown that its antidepressant efficacy is maintained for periods of up to 24 weeks following 6 or 8 weeks of initial treatment (32 weeks total). In one study, patients were assigned randomly to placebo or to the same dose of citalopram (20 to 60 mg/day) during maintenance treatment as they had received during the acute stabilization phase, while in the other study, patients were assigned randomly to continuation of citalopram 20 or 40 mg/day, or placebo, for maintenance treatment. In the latter study, the rates of relapse to depression were similar for the two dose groups (see Clinical Trials under CLINICAL PHARMACOLOGY). Based on these limited data, it is not known whether the dose of citalopram needed to maintain euthymia is identical to the dose needed to induce remission. If adverse reactions are bothersome, a decrease in dose to 20 mg/day can be considered.

    Discontinuation of Treatment with Citalopram

    Symptoms associated with discontinuation of citalopram and other SSRIs and SNRIs have been reported (see PRECAUTIONS). Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.

    Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders

    At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with citalopram. Conversely, at least 14 days should be allowed after stopping citalopram before starting an MAOI intended to treat psychiatric disorders (see CONTRAINDICATIONS).

    Use of Citalopram with Other MAOIs, Such as Linezolid or Methylene Blue Do not start citalopram in a patient who is being treated with linezolid or intravenous methylene blue because there is an increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered (see CONTRAINDICATIONS).

    In some cases, a patient already receiving citalopram therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, citalopram should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with citalopram may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue (see WARNINGS).

    The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with citalopram is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use (see WARNINGS).

  • HOW SUPPLIED

    Citalopram tablets USP, 10 mg are brown, round, biconvex, film coated tablets embossed "RDY" on one side and "342" on other side and are supplied in bottles of 30, 60,100, 500 and unit dose package of 100 (10 × 10).

    Bottles of 30                                         NDC: 55111-342-30

    Bottles of 60                                         NDC: 55111-342-60

    Bottles of 100                                       NDC: 55111-342-01

    Bottles of 500                                       NDC: 55111-342-05

    Unit dose package of 100 (10 x 10)     NDC: 55111-342-78

    Citalopram tablets USP, 20 mg are pink, round, biconvex, film coated tablets embossed ‘RDY’                                                                                                    343

    on one side and scored on other side and are supplied in bottles of 30, 60,100, 500 and unit dose package of 100 (10 x 10).

    Bottles of 30                                                      NDC: 55111-343-30

    Bottles of 60                                                      NDC: 55111-343-60

    Bottles of 100                                                    NDC: 55111-343-01

    Bottles of 500                                                    NDC: 55111-343-05

    Unit dose package of 100 (10 x 10)                  NDC: 55111-343-78

    Citalopram tablets USP, 40 mg are white, round, biconvex, film coated tablets embossed ‘RDY’                                     

                                               344

    on one side and scored on other side and are supplied in bottles of 30, 60,100, 500 and unit dose package of 100 (10 x 10).

    Bottles of 30                                                       NDC: 55111-344-30

    Bottles of 60                                                       NDC: 55111-344-60

    Bottles of 100                                                     NDC: 55111-344-01

    Bottles of 500                                                     NDC: 55111-344-05

    Unit dose package of 100 (10 x 10)                   NDC: 55111-344-78

    Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

  • ANIMAL TOXICOLOGY

    Retinal Changes in Rats

    Pathologic changes (degeneration/atrophy) were observed in the retinas of albino rats in the 2-year carcinogenicity study with citalopram. There was an increase in both incidence and severity of retinal pathology in both male and female rats receiving 80 mg/kg/day (13 times the maximum recommended daily human dose of 60 mg on a mg/m2 basis). Similar findings were not present in rats receiving 24 mg/kg/day for two years, in mice treated for 18 months at doses up to 240 mg/kg/day, or in dogs treated for one year at doses up to 20 mg/kg/day (4, 20, and 10 times, respectively, the maximum recommended daily human dose on a mg/m2 basis).

    Additional studies to investigate the mechanism for this pathology have not been performed, and the potential significance of this effect in humans has not been established.

    Cardiovascular Changes in Dogs

    In a one-year toxicology study, 5 of 10 beagle dogs receiving oral doses of 8 mg/kg/day (4 times the maximum recommended daily human dose of 60 mg on a mg/m2 basis) died suddenly between weeks 17 and 31 following initiation of treatment. Although appropriate data from that study are not available to directly compare plasma levels of citalopram (CT) and its metabolites, demethylcitalopram (DCT) and didemethylcitalopram (DDCT), to levels that have been achieved in humans, pharmacokinetic data indicate that the relative dog-to-human exposure was greater for the metabolites than for citalopram. Sudden deaths were not observed in rats at doses up to 120 mg/kg/day, which produced plasma levels of CT, DCT, and DDCT similar to those observed in dogs at doses of 8 mg/kg/day. A subsequent intravenous dosing study demonstrated that in beagle dogs, DDCT caused QT prolongation, a known risk factor for the observed outcome in dogs. This effect occurred in dogs at doses producing peak DDCT plasma levels of 810 to 3250 nM (39 to 155 times the mean steady state DDCT plasma level measured at the maximum recommended human daily dose of 60 mg). In dogs, peak DDCT plasma concentrations are approximately equal to peak CT plasma concentrations, whereas in humans, steady state DDCT plasma concentrations are less than 10% of steady state CT plasma concentrations. Assays of DDCT plasma concentrations in 2020 citalopram-treated individuals demonstrated that DDCT levels rarely exceeded 70 nM; the highest measured level of DDCT in human overdose was 138 nM. While DDCT is ordinarily present in humans at lower levels than in dogs, it is unknown whether there are individuals who may achieve higher DDCT levels. The possibility that DCT, a principal metabolite in humans, may prolong the QT interval in dogs has not been directly examined because DCT is rapidly converted to DDCT in that species.

    Rx Only

    Manufactured by:
    Dr. Reddy's Laboratories Limited
    Bachupally – 500 090 INDIA

    Revised: 0219

  • MEDICATION GUIDE

    Medication Guide

    Citalopram Tablets, USP

    (sye-TAL-oh-pram)

    Read the Medication Guide that comes with citalopram tablets before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. Talk with your healthcare provider if there is something you do not understand or want to learn more about.

    What is the most important information I should know about citalopram tablets?

    Citalopram tablets and other antidepressant medicines may cause serious side effects, including: 

    1. Suicidal thoughts or actions:

    Keep all follow-up visits with your healthcare provider and call between visits if you are worried about symptoms.

    Call your healthcare provider right away if you have any of the following symptoms, or call 911 if an emergency, especially if they are new, worse, or worry you:

    Call your healthcare provider right away if you have any of the following symptoms, or call 911 if an emergency. Citalopram tablets may be associated with these serious side effects:

    2. Changes in the electrical activity of your heart (QT prolongation and Torsade de Pointes).

    This condition can be life threatening. The symptoms may include:

    3.  Serotonin Syndrome. This condition can be life-threatening and may include:

    4.  Severe allergic reactions:

    5.  Abnormal bleeding: Citalopram tablets and other antidepressant medicines may increase your risk of bleeding or bruising, especially if you take the blood thinner warfarin (Coumadin®, Jantoven®), a non-steroidal antiinflammatory drug (NSAIDs, like ibuprofen or naproxen), or aspirin.

    6. Seizures or convulsions

    7.  Manic episodes:

    8. Changes in appetite or weight.

    Children and adolescents shouldhave height and weight monitoredduring treatment.

    9. Low salt (sodium) levels in the blood. Elderly people may be atgreater risk for this.

    Symptoms mayinclude:

    10. Visual problems

    Only some people are at risk for these problems. You may want to undergo an eye examination to see if you are at risk and receive preventative treatment if you are.

    Do not stop citalopram tablets without first talking to your healthcare provider. 

    Stopping citalopram tablets too quickly may cause serious symptoms including:

    What are citalopram tablets?

    Citalopram tablets are prescription medicine used to treat depression. It is important to talk with your healthcare provider about the risks of treating depression and also the risks of not treating it. You should discuss all treatment choices with your healthcare provider. Citalopram tablets are also used to treat:

    Who should not take Citalopram tablets?

    Do not take citalopram tablets if you:

    People who take citalopram tablets close in time to an MAOI may have serious or even life-threatening side effects. Get medical help right away if you have any of these symptoms:

    What should I tell my healthcare provider before taking citalopram tablets? Ask if you are not sure.

    Before starting citalopram tablets, tell your healthcare provider if you

    Tell your healthcare provider about all the medicines that you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Citalopram tablets and some medicines may interact with each other, may not work as well, or may cause serious side effects. 

    Your healthcare provider or pharmacist can tell you if it is safe to take citalopram tablets with your other medicines. Do not start or stop any medicine while taking citalopram tablets without talking to your healthcare provider first.

    If you take citalopram tablets, you should not take any other medicines that contain citalopram or escitalopram including: Lexapro.

    How should I take citalopram tablets?

    What should I avoid while taking citalopram tablets?

    Citalopram tablets can cause sleepiness or may affect your ability to make decisions, think clearly, or react quickly. You should not drive, operate heavy machinery, or do other dangerous activities until you know how citalopram tablets affects you. Do not drink alcohol while using citalopram tablets. 

    What are the possible side effects of citalopram tablets? 

    Citalopram tablets may cause serious side effects, including: 

    See “What is the most important information I should know about citalopram tablets?” 

    Common possible side effects in people who take citalopram tablets include:

    Other side effects in children and adolescents include:

    Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of citalopram tablets. For more information, ask your healthcare provider or pharmacist.

    CALL YOUR DOCTOR FOR MEDICAL ADVICE ABOUT SIDE EFFECTS. YOU MAY REPORT SIDE EFFECTS TO THE FDA AT 1- 800-FDA-1088.

    How should I store citalopram tablets?

    Keep citalopram tablets and all medicines out of the reach of children. 

    General information about citalopram tablets

    Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use citalopram tablets for a condition for which it was not prescribed. Do not give citalopram tablets to other people, even if they have the same condition. It may harm them.  

    This Medication Guide summarizes the most important information about citalopram tablets. If you would like more information, talk with your healthcare provider. You may ask your healthcare provider or pharmacist for information about citalopram tablets that is written for healthcare professionals. 

    For more information about citalopram tablets call 1-888-375-3784.

    What are the ingredients in citalopram tablets?  

    Active ingredient: citalopram hydrobromide  

    Inactive ingredients: colloidal silicon dioxide, copovidone, croscarmellose sodium, hypromellose 5 cP, hypromellose 6 cP, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, starch and titanium dioxide. 

    This Medication Guide has been approved by the U.S. Food and Drug Administration.  

    To reorder additional Medication Guides, contact Dr. Reddy's customer service at 1-866-733-3952

    Rx Only 

    Manufactured by:

    Dr. Reddy’s Laboratories Limited

    Bachupally - 500 090 INDIA

    Revised: 0219

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION

    10 mg Container Label

    container1

  • PRINCIPAL DISPLAY PANEL

    10 mg Blister Carton Label

    carton1

  • PRINCIPAL DISPLAY PANEL

    20 mg Container Label

    container2

  • PRINCIPAL DISPLAY PANEL

    20 mg Blister Carton Label

    carton2

  • PRINCIPAL DISPLAY PANEL

    40 mg Container Label

    container3

  • PRINCIPAL DISPLAY PANEL

    40 mg Blister Carton Label

    carton3

  • INGREDIENTS AND APPEARANCE
    CITALOPRAM HYDROBROMIDE 
    citalopram hydrobromide tablet, film coated
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 55111-342
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Citalopram hydrobromide (UNII: I1E9D14F36) (Citalopram - UNII:0DHU5B8D6V) Citalopram10 mg
    Inactive Ingredients
    Ingredient NameStrength
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    Copovidone K25-31 (UNII: D9C330MD8B)  
    croscarmellose sodium (UNII: M28OL1HH48)  
    HYPROMELLOSE 2910 (5 MPA.S) (UNII: R75537T0T4)  
    HYPROMELLOSE 2910 (6 MPA.S) (UNII: 0WZ8WG20P6)  
    lactose monohydrate (UNII: EWQ57Q8I5X)  
    magnesium stearate (UNII: 70097M6I30)  
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    polyethylene glycol 400 (UNII: B697894SGQ)  
    starch, corn (UNII: O8232NY3SJ)  
    titanium dioxide (UNII: 15FIX9V2JP)  
    ferric oxide red (UNII: 1K09F3G675)  
    ferric oxide yellow (UNII: EX438O2MRT)  
    ferrosoferric oxide (UNII: XM0M87F357)  
    Product Characteristics
    ColorBROWNScoreno score
    ShapeROUNDSize6mm
    FlavorImprint Code RDY;342
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 55111-342-3030 in 1 BOTTLE; Type 0: Not a Combination Product10/28/2004
    2NDC: 55111-342-6060 in 1 BOTTLE; Type 0: Not a Combination Product10/28/2004
    3NDC: 55111-342-01100 in 1 BOTTLE; Type 0: Not a Combination Product10/28/2004
    4NDC: 55111-342-05500 in 1 BOTTLE; Type 0: Not a Combination Product10/28/2004
    5NDC: 55111-342-7810 in 1 CARTON10/28/2004
    5NDC: 55111-342-7910 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA07703810/28/2004
    CITALOPRAM HYDROBROMIDE 
    citalopram hydrobromide tablet, film coated
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 55111-343
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Citalopram hydrobromide (UNII: I1E9D14F36) (Citalopram - UNII:0DHU5B8D6V) Citalopram20 mg
    Inactive Ingredients
    Ingredient NameStrength
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    Copovidone K25-31 (UNII: D9C330MD8B)  
    croscarmellose sodium (UNII: M28OL1HH48)  
    HYPROMELLOSE 2910 (5 MPA.S) (UNII: R75537T0T4)  
    HYPROMELLOSE 2910 (6 MPA.S) (UNII: 0WZ8WG20P6)  
    lactose monohydrate (UNII: EWQ57Q8I5X)  
    magnesium stearate (UNII: 70097M6I30)  
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    polyethylene glycol 400 (UNII: B697894SGQ)  
    starch, corn (UNII: O8232NY3SJ)  
    titanium dioxide (UNII: 15FIX9V2JP)  
    ferric oxide red (UNII: 1K09F3G675)  
    Product Characteristics
    ColorPINKScore2 pieces
    ShapeROUNDSize8mm
    FlavorImprint Code RDY;343
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 55111-343-3030 in 1 BOTTLE; Type 0: Not a Combination Product10/28/2004
    2NDC: 55111-343-6060 in 1 BOTTLE; Type 0: Not a Combination Product10/28/2004
    3NDC: 55111-343-01100 in 1 BOTTLE; Type 0: Not a Combination Product10/28/2004
    4NDC: 55111-343-05500 in 1 BOTTLE; Type 0: Not a Combination Product10/28/2004
    5NDC: 55111-343-7810 in 1 CARTON10/28/2004
    5NDC: 55111-343-7910 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA07703810/28/2004
    CITALOPRAM HYDROBROMIDE 
    citalopram hydrobromide tablet, film coated
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 55111-344
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Citalopram hydrobromide (UNII: I1E9D14F36) (Citalopram - UNII:0DHU5B8D6V) Citalopram40 mg
    Inactive Ingredients
    Ingredient NameStrength
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    Copovidone K25-31 (UNII: D9C330MD8B)  
    croscarmellose sodium (UNII: M28OL1HH48)  
    HYPROMELLOSE 2910 (5 MPA.S) (UNII: R75537T0T4)  
    HYPROMELLOSE 2910 (6 MPA.S) (UNII: 0WZ8WG20P6)  
    lactose monohydrate (UNII: EWQ57Q8I5X)  
    magnesium stearate (UNII: 70097M6I30)  
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    polyethylene glycol 400 (UNII: B697894SGQ)  
    starch, corn (UNII: O8232NY3SJ)  
    titanium dioxide (UNII: 15FIX9V2JP)  
    Product Characteristics
    ColorWHITEScore2 pieces
    ShapeROUNDSize10mm
    FlavorImprint Code RDY;344
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 55111-344-3030 in 1 BOTTLE; Type 0: Not a Combination Product10/28/2004
    2NDC: 55111-344-6060 in 1 BOTTLE; Type 0: Not a Combination Product10/28/2004
    3NDC: 55111-344-01100 in 1 BOTTLE; Type 0: Not a Combination Product10/28/2004
    4NDC: 55111-344-05500 in 1 BOTTLE; Type 0: Not a Combination Product10/28/2004
    5NDC: 55111-344-7810 in 1 CARTON10/28/2004
    5NDC: 55111-344-7910 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA07703810/28/2004
    Labeler - Dr. Reddy's Laboratories Limited (650562841)
    Establishment
    NameAddressID/FEIBusiness Operations
    Dr.Reddy's Laboratories Limited918608162analysis(55111-342, 55111-343, 55111-344) , manufacture(55111-342, 55111-343, 55111-344)

  • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.